Warfarin Management in Patients with Atrial Fibrillation — Current Practice Study
CADTH Optimal Use Report, No. 1.2D
The objective of this current practice study was to explore the views and experiences of health care professionals and patients with atrial fibrillation regarding the use of warfarin and management of warfarin therapy for the prevention of thromboembolic events.
This report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH).
This report is based on information on practice behaviours available at the time of report preparation and has not been reviewed by peers. The information in this report should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this report.
CADTH takes sole responsibility for the final form and content of this report. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government.
Production of this report is made possible through a financial contribution from Health Canada.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/